Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Skyler Martin

Nurse Practitioner, Family Foley, AL Nurse Practitioner

NPI 1093195091 CMS profile 11031781

669 S McKenzie St, Foley, AL 36535

Open in the dashboard

General payments

$16,888

581 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Skyler Martin of Foley, AL is reported in the CMS Open Payments database as having received $16,888 across 581 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,295 111
2024 General $2,532 114
2023 General $1,990 99
2022 General $2,886 132
2021 General $7,185 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Skyler Martin
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Skyler Martin were reported at $2,295. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Skyler Martin Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $7,185 $124 $35–$379 $132
2022 $2,886 $141 $44–$430 $149
2023 $1,990 $154 $49–$476 $160
2024 $2,532 $165 $51–$504 $164
2025 $2,295 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Myriad Genetic Laboratories, Inc. $5,577 13 payments
  2. Novartis Pharmaceuticals Corporation $1,175 63 payments
  3. AstraZeneca Pharmaceuticals LP $929 37 payments
  4. Merck Sharp & Dohme Corporation $865 40 payments
  5. Janssen Biotech, Inc. $576 33 payments
  6. Celgene Corporation $572 29 payments
  7. Daiichi Sankyo Inc. $562 28 payments
  8. Amgen Inc. $504 26 payments
  9. Eisai Inc. $446 23 payments
  10. Incyte Corporation $367 20 payments
  11. Other $5,315 269 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,440 570 payments
  2. Consulting Fee $5,343 8 payments
  3. Education $75 2 payments
  4. Travel and Lodging $30 1 payment
Products named General payments · program years 2021–2025
  1. myRisk $5,327 11 payments
  2. KEYTRUDA $757 35 payments
  3. KISQALI $432 22 payments
  4. Lenvima $406 21 payments
  5. ENHERTU $389 20 payments
  6. LYNPARZA $381 6 payments
  7. LIBTAYO $357 14 payments
  8. JAKAFI $350 19 payments
  9. VERZENIO $331 17 payments
  10. REBLOZYL $327 14 payments
  11. Other $10,457 541 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

309

Median for Nurse Practitioner: 389

Drug cost

$6,590

Median for Nurse Practitioner: $21,885

Branded share of claims

44.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 86 $2,335
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 36 $1,969
Oxycodone Hcl Generic 23 $554
Morphine Sulfate Er Morphine Sulfate Brand 15 $526
Hydroxyurea Generic 17 $337
Gabapentin Generic 33 $291
Tramadol Hcl Generic 19 $159
Prednisone Generic 22 $154
Temazepam Generic 19 $98
Zolpidem Tartrate Generic 14 $81

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$223,644

Of which drugs: $187,857

Medicare patients

406

Average age 75

Services billed

16,585

244 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Cancer 41%
Ischemic heart disease 35%
Diabetes 34%
Atrial fibrillation 25%
Chronic kidney disease 25%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 1,020 $20,985
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 114 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 53 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $301
  • Merck Sharp & Dohme Corporation $24
$325 — —
ENHERTU
  • Daiichi Sankyo Inc. $101
  • AstraZeneca Pharmaceuticals LP $41
$142 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $140
$140 — —
Pomalyst
  • Celgene Corporation $100
$100 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $95
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 53 with Patron

Records

581 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record